Bayer forms joint venture in Russia; Aerie Pharma reviews upbeat data for glaucoma drug;

 @FierceBiotech: Roche, pharma slice and dice DNA data to exploit cancer weaknesses. Story | Follow @FierceBiotech

 @JohnCFierce: Bloomberg's sized up the PCSK9 rivalry between Amgen and Sanofi/Regeneron. Article | Follow @JohnCFierce

 @RyanMFierce: Any idea what uniQure's gene therapy should cost? Here's our report on approval in EU. More | Follow @RyanMFierce

> Bayer Healthcare has joined forces with Russian drugmaker Medsintez to produce diagnostic imaging agents and pharmaceuticals for patients in Russia. Release

> Aerie Pharmaceuticals generated upbeat results in a Phase IIa trial of its therapy called AR-13324 for patients with glaucoma. Release

> RayBiotech has tapped Abeome for 300 monoclonal antibodies focused on ovarian cancer. Item

> Digna Biotech, a Spain-based biotech focused on liver diseases, has opened its first U.S. office in Pennsylvania. Article

> Isis ($ISIS) has received a $1.25 million payment from Pfizer ($PFE) because of Pfizer's decision to advance development of EXC 001 or PF-06473871. Release

> Montreal-based Alethia Biotherapeutics, a developer of monoclonal antibodies against bone disases, raised $4.7 million from AgeChem Venture Fund, BDC Venture Capital, GO Capital and Cellscript. Release

Pharma News

@FiercePharma: ICYMI yesterday: Top 15 drug patent losses for 2013. The patent cliff isn't over. Report | Follow @FiercePharma

> U.K. finally approves Roche's Zelboraf and BMS' Yervoy. Article

> J&J settles a boatload of Levaquin cases. News

> After Wellbutrin fiasco, FDA takes a look at generic equivalence. Story

Medical Device News

 @FierceMedDev: St. Jude announced it is cutting 500 more jobs in through its restructuring plan. 8-K | Follow @FierceMedDev

 @MarkHFierce: Taiwan wants to get on the medical device bandwagon and has plans to jumpstart its local industry. News | Follow @MarkHFierce

 @DamianFierce: Ex-Stryker CEO Stephen MacMillan has landed on his feet after the public breakup, taking the reins at sBioMed. More | Follow @DamianFierce

> Report: European Commission must speed up creation of tougher medical implant regs. Story

> Ex-Stryker CEO to head disinfectant firm. Item

> Investors punish Abiomed over Impella investigation news. Report

And Finally… More stuff to worry parents: Researchers find that food allergies in children can make them bull's-eyes for bullies. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.